Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia

Dec 11, 2024Nature

Lipid nanoparticles carrying placenta-targeted VEGF mRNA improve pre-eclampsia in mice

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

A placenta-tropic lipid nanoparticle (LNP 55) mediates more than 100-fold greater mRNA delivery to the placenta compared to an FDA-approved formulation in pregnant mice.

Pre-eclampsia affects 3-5% of all pregnancies and is a significant cause of maternal and fetal health issues.
LNP 55 encapsulating vascular endothelial growth factor (VEGF) mRNA can resolve maternal hypertension in models of pre-eclampsia.
This treatment improves fetal health and partially restores placental blood vessel formation and immune response.
The proposed delivery mechanism involves the adsorption of β-glycoprotein I, which targets the placenta.

AI simplified

Pre-eclampsia is a placental disorder that affects 3-5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide. With no drug available to slow disease progression, engineering ionizable lipid nanoparticles (LNPs) for extrahepatic messenger RNA (mRNA) delivery to the placenta is an attractive therapeutic option for pre-eclampsia. Here we use high-throughput screening to evaluate a library of 98 LNP formulations in vivo and identify a placenta-tropic LNP (LNP 55) that mediates more than 100-fold greater mRNA delivery to the placenta in pregnant mice than a formulation based on the Food and Drug Administration-approved Onpattro LNP (DLin-MC3-DMA). We propose an endogenous targeting mechanism based on β-glycoprotein I adsorption that enables LNP delivery to the placenta. In both inflammation- and hypoxia-induced models of pre-eclampsia, a single administration of LNP 55 encapsulating vascular endothelial growth factor (VEGF) mRNA resolves maternal hypertension until the end of gestation. In addition, with our VEGF mRNA LNP 55 therapeutic, we demonstrate improvements in fetal health and partially restore placental vasculature, the local and systemic immune landscape and serum levels of soluble Fms-like tyrosine kinase-1, a clinical biomarker of pre-eclampsia. Together, these results demonstrate the potential of this mRNA LNP platform for treating placental disorders such as pre-eclampsia. 1,2 3 1 2

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief